• Mashup Score: 0
    William C. Huang, MD @UroWCH @NYUUrology @nyulangone @ - 3 year(s) ago

    William C. Huang, M.D., FACS, Associate Professor and Vice-Chair of Urology at NYU Langone Health, Principal Investigator of the OPTIMA II trial speaks abo

    Source: www.oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      PD43-02 Primary Chemoablation Of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102 William C. Huang, MD @UroWCH @NYUUrology @nyulangone @UroGenPharma #UGN-102 #nyulangonecancer #BladderCancer https://t.co/41iKKCASPI...?channelName=cancernewsupdate https://t.co/LAgMX1vnw2